Kite Pharma Inc Cmn (KITE) 54.57 $KITE Kite Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 5:07 AM

Kite Pharma Inc Cmn (KITE) 54.57 $KITE

Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
BusinessWire - Tue Sep 20, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to multiple T-cell receptor (TCR) based product candidates for the treatment of tumors expressing mutated KRAS antigens.
KITE: 54.57 (-0.36)

Covered Call reports for Disney, Kite Pharma, Ford, CONSOL Energy and Caterpillar Inc. include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CAT, CNX, DIS, F, and KITE.
F: 12.17 (-0.01), CNX: 17.40 (-0.17), KITE: 54.57 (-0.36), DIS: 93.27 (-0.14), CAT: 82.44 (-1.06)

Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma
PR Newswire - Mon Sep 12, 7:05AM CDT
Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, Stock-Callers.com has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:
RDUS: 56.52 (-0.89), NWBO: 0.53 (-0.02), KITE: 54.57 (-0.36), SPPI: 4.72 (-0.09)

Kite Pharma to Participate in September 2016 Investor Conferences
BusinessWire - Wed Aug 31, 3:05PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will participate in a panel at the 11th Annual Citi Biotech Conference and a fireside chat discussion at the Morgan Stanley Global Healthcare Conference.
KITE: 54.57 (-0.36), MS: 31.91 (-0.33)

Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement
ACCESSWIRE - Mon Aug 29, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), announced today that its research partners at the University of Minnesota cancer center are collaborating with the National Institutes of Health to accelerate commercialization of their promising TriKE cancer-fighting platform.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)

Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
BusinessWire - Fri Aug 19, 7:00AM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that two of its key advisors and scientific collaborators, both pioneers in the field of cancer immunotherapy, have received the renowned Novartis Prize for Clinical Immunology.
KITE: 54.57 (-0.36), NVS: 81.48 (-0.55)

Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 54.46 (-0.22), CBM: 46.60 (+0.30), KITE: 54.57 (-0.36), AMGN: 174.80 (-0.82)

Kite Pharma Reports Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 08, 3:05PM CDT
--KTE-C19 Biologics License Application Filing Planned in Late 2016; Commercial Launch of KTE-C19 Expected in 2017
KITE: 54.57 (-0.36)

5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 243.94 (+0.51), ENDP: 23.39 (+3.13), JNJ: 118.81 (-0.65), RARE: 72.60 (-1.45), KITE: 54.57 (-0.36), HZNP: 19.43 (+0.02), NVS: 81.48 (-0.55)

Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 5:56AM CDT
With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
KITE: 54.57 (-0.36), INCY: 88.98 (-0.29), AMGN: 174.80 (-0.82), IONS: 35.12 (+0.10)

Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Wed Aug 03, 3:16PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at the Canaccord Genuity 36th Annual Growth Conference.
KITE: 54.57 (-0.36)

Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016
BusinessWire - Mon Aug 01, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report second quarter 2016 financial results on Monday, August 8, 2016, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 PM Eastern Time (1:30 PM Pacific Time).
KITE: 54.57 (-0.36)

Oxis International Comments On New York Times Article About Cancer Immunotherapy
ACCESSWIRE - Mon Aug 01, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, today commented on a New York Times article that examined cancer immunotherapy.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)

Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
BusinessWire - Wed Jul 27, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies. The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.
KITE: 54.57 (-0.36)

Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
BusinessWire - Mon Jun 20, 3:55PM CDT
--Preparations on Track to Launch Lead Product Candidate KTE-C19 in 2017
KITE: 54.57 (-0.36)

Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
BusinessWire - Mon Jun 20, 7:05AM CDT
Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers.
KITE: 54.57 (-0.36)

Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
BusinessWire - Wed Jun 08, 7:00AM CDT
--SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an understudied patient population
KITE: 54.57 (-0.36)

Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 90.63 (-1.49), FCX: 10.63 (-0.35), ILMN: 179.33 (-0.01), XOM: 83.45 (-0.09), MYL: 42.06 (-0.53), BA: 131.78 (-0.09), SLB: 75.92 (-1.09), AA: 9.76 (-0.02), LYB: 77.39 (-0.79), RIG: 9.10 (-0.55), KITE: 54.57 (-0.36), CF: 22.63 (-0.60), CHK: 6.63 (-0.24), EOG: 89.75 (-2.86), CVX: 99.22 (-0.76), ECL: 119.04 (-0.10)

Why is Kite Pharma (KITE) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 3:42PM CDT
On Monday, shares of clinical-stage biopharmaceutical company Kite Pharma Inc. (KITE) are soaring, up over 12% in afternoon trading after the company announced results from SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research).
KITE: 54.57 (-0.36)

Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
BusinessWire - Mon Jun 06, 6:45AM CDT
--Overall response rate was 26% with only 8% achieving a complete response
KITE: 54.57 (-0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Where Winds Meet Celebrates 1st Anniversary With New Region

A Staggering Universe Deepens: Hutuo's Introduction Just when you think you've seen it all, NetEase Games and Everstone Studio go and launch Hutuo, a compelling addition to the already sprawling universe of Where Winds Meet. On the occasion of its first global anniversary, this epic Wuxia ARPG throws players into the mud-soaked, steel-clashing chaos of a warzone, testing...

OI Investors Crack Down: Class Action Filing Looms

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

Biel Crystal's AI Vision Earns Forbes Recognition

What's Cookin' in Smart Manufacturing? Sometimes, the big news isn’t just about the dollars—it’s about who’s turning heads with their tech wizardry. That's what's happening over at Biel Crystal. Crafting Smarter Manufacturing This Hong Kong-based dynamo isn't your run-of-the-mill manufacturer. Biel Crystal, with its jaw-dropping setup of over 100,000 employees...

Aluminum Fluoride Market to Hit $3.3B by 2031

Eye on the Aluminum Fluoride Surge Cracking open the numbers, the aluminum fluoride market is projected to swell from $2.48 billion in 2026 to a hefty $3.30 billion by 2031, trucking along at a CAGR of 5.9%. That's no small potatoes in the world of industrial materials. Scratch the surface, and you’ll see what's fueling this climb—think of it as a bellwether for...

Will Hair Loss Drugs Challenge Transplant Clinics?

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Revving Up: TIER IV and Komatsu's Bold Auto Move

Steering Toward a Driverless Future When you think of technology leaders, dump trucks might not be the first thing that comes to mind. But here we are, with TIER IV and Komatsu sparking up a collaboration to drive their heavy-duty fleet straight into the future. We're talking autonomous driving systems for three brawny dump truck models—the HD785, HD605, and...

Procon Uses Robotics to Revamp Cruise Terminal 5

Building Bigger with Robotics at Port Canaveral Robots on a construction site sounds like sci-fi, right? But it's the reality at Port Canaveral's Cruise Terminal 5, where Procon is rolling out its robotic tech magic. This ain't your everyday wrench-and-spanner job; we're talking remote-controlled bots capturing 360-degree images. “Regular reality capture can help teams...

Schools Reimagine Yearbooks with Interactive Archives

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Natura's 3Q26 Performance: Navigating Bottlenecks and Potential

Unexpected Performance Amidst Challenging Circumstances I'll tell you, navigating through operational bottlenecks is no small feat, but Natura seems to be brewing its own survival recipe. They reported a net income of BRL 49 million in the third quarter of 2026, clawing back from a net loss of BRL 119 million in the previous year. That's no magic trick; it's a reflection...

Biodiversity Monitoring Poised for $11.39 Billion Boom

A Billion-Dollar Market on the Rise Picture this: you're watching the world make a monumental shift towards sustainability in real-time. The biodiversity monitoring market is on a gallop, poised to grow from a modest USD 7.17 billion in 2026 to a hearty USD 11.39 billion by 2031. That's a CAGR of 9.7%—a pace that soothes the nerves of any investor weary of the whims of...